🟢 Opus Genetics is trading 6.1% up in pre-market ahead of September 9 topline data webcast

Opus Genetics is trading 6.1% up in pre-market at $4.72 after announcing a September 9 investor webcast for topline Cohort 1 data from its Phase 1/2 OPGx-BEST1 study.

• Shares gained 16.19% to $4.45 on September 2 and rose 5.80% on September 1.
• Full clinical data are also planned for upcoming ophthalmology conferences.
• The announcement reinforces a near-term binary gene-therapy catalyst.